Clinical trials: Signs and Symptoms, Digestive
Inflammatory Bowel Disease
Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease
The study is a prospective, non-controlled, open-label multi-centre pilot safety study of iron isomaltoside 1000 (Monofer®) administered to subjects with anaemia and Inflammatory Bowel Disease (IBD).
- Trial name
- IBD-02 (NCT01599702)
- Testing
- Iron Isomaltoside 1000
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Pharmacosmos A/S
Hepatitis B, Chronic
Study of AHB-171 in Chronic Hepatitis B Participants
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AHB-171 in participants with chronic hepatitis B (CHB).
- Trial name
- EXTEND-101 (NCT07617194)
- Testing
- AHB-171, Nucleos(t)ide Analogue (NA)
- Where
- 2 sites in Hong Kong, New Zealand
- Volunteers
- 144 people
- Sponsor
- AusperBio Therapeutics Inc.
Gastrointestinal, Tolerance
Gastrointestinal Tolerance of Erythritol-containing Beverages in Young Children
Purpose of this study: assess the maximum tolerated bolus dose of erythritol, delivered in a clear beverage, compared with placebo (saccharose) in 4-6 year old children.
- Trial name
- NCT02016703
- Testing
- Erythritol drink
- Where
- 3 sites in France
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Cargill
Cryptosporidiosis, HIV Infections
Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)
To evaluate the safety and efficacy of diclazuril capsules compared with placebo capsules as treatment of cryptosporidial related diarrhea in AIDS patients.
- Trial name
- NCT00002027
- Testing
- Diclazuril
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Janssen, LP
Colorectal Cancer, Head and Neck Cancer
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
The study is expected to identify a safe dose of BMS-754807 to be given in combination with a standard dose of cetuximab and the recommended dose or dose range for Phase II studies.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Neoplasm Metastasis
- Trial name
- NCT00908024
- Testing
- BMS-754807, cetuximab (Erbitux®)
- Where
- 5 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Bristol-Myers Squibb
Anorexia Nervosa, Constipation
The Role of Lactobacillus Reuteri in Children and Adolescents With Anorexia Nervosa
The aim of this study is to investigate whether Lactobacillus reuteri could have a beneficial role in treatment of children and adolescents with Anorexia nervosa who develop motility disorder due to the malnutrition regarding the…
- Trial name
- NCT02004288
- Testing
- Lactobacillus reuteri Protectis DSM17938
- Where
- Croatia
- Volunteers
- 31 people
- Sponsor
- BioGaia AB
Irritable Bowel Syndrome, Constipation
Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.
- Trial name
- NCT00399542
- Testing
- Lubiprostone
- Volunteers
- 581 people
- Sponsor
- Sucampo Pharma Americas, LLC
Liver Cirrhosis
Alfapump-albumin Replacement Therapy
The study will be a single centre, open-label trial. The patients will have a diagnosis of refractory ascites and will meet specified inclusion/exclusion criteria Informed consent will be obtained from all patients.
- Trial name
- NCT02448160
- Testing
- alfapump, salt-poor Human Albumin solution
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Sequana Medical N.V.
Healthy Volunteers
Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.
The study is designed to evaluate the BE and adhesion properties of granisetron transdermal patches manufactured at 2 different sites. The study has been designed in accordance with the FDA Guidance for Industry.
- Trial name
- NCT05027646
- Testing
- Sancuso - Part 1, Sancuso - Part 2
- Where
- United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin, Inc.
Chemotherapy-induced Nausea and Vomiting
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
The objective of this Open Label Study is to evaluate effects of Rolapitant IV solution, and its metabolite, on the pharmacokinetics (PK) of the P-gp substrate (digoxin), the BCRP substrate (sulfasalazine), and multiple…
- Trial name
- NCT02434861
- Testing
- Rolapitant, Digoxin, Sulfasalazine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Tesaro, Inc.
Chronic Hepatitis B
An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection
To provide open-label entecavir to subjects who have completed previous blinded entecavir trials in Japan and are assessed by the investigator as likely to benefit from additional anti-hepatitis B therapy
- Trial name
- NCT01037062
- Testing
- Entecavir
- Where
- 48 sites in Japan
- Volunteers
- 282 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis B
A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
This is a study of sequential therapy with AHB-137 injection followed by TVAX-008 injection in participants living with Chronic Hepatitis B (CHB).
- Trial name
- NCT07897448
- Testing
- AHB-137, TVAX-008
- Volunteers
- 105 people
- Sponsor
- Grand Theravac Life Sciences (Hangzhou) Co., Ltd.
Pancreatic Neoplasms
A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer
The purpose of this study is to determine if imexon in combination with gemcitabine could improve overall survival as compared to gemcitabine alone in subjects with pancreatic cancer that has spread to other organs such as the…
- Trial name
- NCT00637247
- Testing
- imexon in combination with gemcitabine
- Where
- 48 sites in United States
- Volunteers
- 142 people
- Sponsor
- AmpliMed Corporation
Crohn's Disease
Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease
The purpose of this study is to determine the safety and efficacy of interferon beta-1a in maintaining remission in patients with Crohn's disease.
- Trial name
- NCT00304252
- Testing
- Interferon beta-1a
- Where
- 5 sites in Germany, Italy and 3 more
- Volunteers
- 192 people
- Sponsor
- EMD Serono
Persistent Infection, Cystic Fibrosis
A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics.
- Trial name
- NCT06159725
- Testing
- CMTX-101
- Where
- 23 sites in United States
- Volunteers
- 43 people
- Sponsor
- Clarametyx Biosciences, Inc.
Opioid-induced Constipation
Evaluation of the Quality of Life of Patients With Opioid-induced Constipation Under Treatment With Naloxegol
Opioid-induced constipation (OIC) is a common feature in patients treated with strong opioids. Such medication is often prescribed together with a laxative (osmotic, emollient), with effectiveness depending on the individual…
- Trial name
- KYONAL (NCT04173858)
- Testing
- Naloxegol
- Where
- Spain
- Volunteers
- 126 people
- Sponsor
- Kyowa Kirin Farmacéutica S.L.U.
Opioid Induced Constipation
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects with Opioid-Induced Constipation
- Trial name
- NCT01459926
- Testing
- TD-1211
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- Glycyx Therapeutics
Chronic Hepatitis B
A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection
Entecavir, 0.5 mg daily, will have clinical efficacy (assessed as an undetectable hepatitis B DNA, <300 copies/mL, by Roche Comprehensive Bio-Analytical System Amplicor polymerase chain reaction assay) that is comparable…
- Trial name
- NCT00393484
- Testing
- Entecavir, Lamivudine
- Where
- 15 sites in South Korea
- Volunteers
- 122 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients
The purpose of this study is to evaluate effectiveness, safety and pharmacokinetics (Explores what the body does to the medication) of TMC435350 in combination with Peginterferon Alfa-2a and Ribavirin in genotype 1 hepatitis C…
- Trial name
- DRAGON (NCT00996476)
- Testing
- TMC435, PegIFNα-2a, RBV
- Where
- 19 sites in Japan
- Volunteers
- 92 people
- Sponsor
- Janssen Pharmaceutical K.K.
Recurrent Clostridium Difficile Infection
Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium…
- Trial name
- PUNCH CD (NCT01925417)
- Testing
- RBX2660 (microbiota suspension)
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- Rebiotix Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.